CT Brain biopsy and infusion


Glioma surgical resection


Radiation Therapy Planning

Information

For information on enrollment, or to refer a patient:

Neurology/Neurosurgery Service
Christy Chessman (Service coordinator)
530 754 0606
chchessman@ucdavis.edu

VMTH Hospital Reception
530 752 1393

Peter J. Dickinson, BVSc, PhD, DACVIM (Neurology)
UC Davis
School of Veterinary Medicine
(530) 752-3412

For more information about
Toca 511 and Toca FC
please visit:

www.tocagen.com

 

Brain Tumor Clinical Study
for Dogs with Glioma

Toca 511 & Toca FC Gene Transfer •
with Surgical Resection & Radiation Therapy

pup pictToca 511 is a nonlytic retroviral replicating vector that delivers a Cytosine Deaminase (CD) gene selectively to cancer cells. Toca FC is an extended-release tablet containing the antifungal drug, 5-FC (flucytosine). Toca FC is used in combination with Toca 511 because CD catalyzes the conversion of 5-FC, to the anti-cancer drug, 5-FU (5-fluorouracil).

Toca 511 is administered transcranially directly into the tumor following stereotactic biopsy. 3-6 weeks following Toca 511, surgical resection will be performed with the option for adjuvant radiation therapy.

The Toca 511 & Toca FC investigational study has been approved by:

 

How It Works

We will be happy to review imaging data, diagnostics or clinical history for potential cases.

Dogs enrolled in the study will have the following procedures financially covered in addition to
Toca 511 ($12,000-15,000)

All treatment decisions will be made in consultation with the owner and referring veterinarian.
Funded by The American Brain Tumor Association- Toca 511 Trial Anouncement

For additional information in brain tumors Click